HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sclerotheraphy with OK-432 for the Treatment of Lymphangiomas.

AbstractPURPOSE:
To evaluate the efficacy of sclerotherapy with OK-432 for lymphangiomas.
MATERIALS AND METHODS:
Retrospective review of twelve patients with lymphangiomas who were treated with OK-432 from 1996 to 2000.
RESULTS:
Twelve patients were treated by sclerotherapy with OK-432. Ten patients were received sclerotherapy with OK-432 as primary therapy, and two were treated as secondary therapy after failure of surgery. Six cases were cystic hygroma (macrocystic); all of them, complete shrinkage was obtained. The other six cases were cavernous lymphangioma (microcystic): two of them, therapy were successful, but four were failed to achieve satisfactory shrinkage. So, they underwent surgical excision after failure of sclerotherapy. The results were excellent in cystic hygroma (success rate; 100%), however moderately poor results were obtained in cavernous lymphangioma (success rate 33.3%).
CONCLUSION:
Intralesional injection of OK-432 is effective therapy for cystic hygroma as a primary therapy.
AuthorsYoung Gwon Wang, Hyung Il Seo, Hae Young Kim
JournalCancer research and treatment (Cancer Res Treat) Vol. 34 Issue 1 Pg. 62-6 (Feb 2002) ISSN: 1598-2998 [Print] Korea (South)
PMID26680845 (Publication Type: Journal Article)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: